Scotts Miracle-Gro (SMG) just posted Q2 2026 results with revenue of US$1.5 billion and basic EPS of US$4.53, while trailing 12 month figures show revenue of US$3.5 billion and EPS of US$3.56. Over the past year, revenue has held around the US$3.4 billion to US$3.5 billion mark on a trailing basis, with EPS moving from US$0.69 in the Q2 2025 trailing window to US$3.56 most recently. This sets up this quarter as an important reference point for how earnings are tracking. With net profit margins currently at 5.9% on a trailing basis versus 1.1% a year earlier, investors will be weighing how durable this profitability shift looks against the latest set of numbers.

See our full analysis for Scotts Miracle-Gro.

With the headline figures on the table, the next step is to see how this earnings profile lines up against the dominant narratives around Scotts Miracle-Gro and where those stories might need updating.

Margins Improve Despite One Off Loss

• On a trailing basis, net profit margin sits at 5.9% compared with 1.1% a year earlier, even though a US$83.8 million one off loss and US$95.3 million of losses from discontinued operations are included in the last 12 months.
• What stands out for the bullish view is that this higher 5.9% margin and trailing EPS of US$3.56 sit alongside cost savings and mix upgrades that bulls expect to support margin expansion. At the same time, the multi year earnings decline of 19% per year and the impact of that US$83.8 million loss show that the path to the higher margin targets in the bullish narrative is not straightforward.
  • Bulls point to over US$100 million of cost savings already captured and a focus on higher margin branded products as reasons margins could keep improving, while the recent margin level is still well below the 35% gross margin goal mentioned in the consensus narrative.
  • The strong year over year earnings improvement of more than 4x on the trailing 12 month view supports the idea that mix and cost actions are helping, although the one off loss reminds you that unusual items can still swing reported profitability.

Stronger recent margins and that sharp earnings rebound are exactly why some investors are revisiting the optimistic case for SMG right now 🐂 Scotts Miracle-Gro Bull Case

Debt Coverage Remains A Key Watchpoint

• Debt coverage by operating cash flow is flagged as weak in the trailing 12 month assessment, which sits alongside multi year earnings falling 19% per year and only modest trailing revenue growth of 1.6% per year.
• Bears focus on this weak debt coverage and the multi year earnings decline as evidence that even with the recent profit rebound, the balance sheet and earnings history keep risk elevated.
  • Critics highlight that the company is carrying debt while also discussing a possible US$500 million to US$1 billion share buyback and a 4.21% dividend yield, which together could compete with debt reduction if cash generation does not strengthen.
  • The leverage ratio of 4.1x net debt to adjusted EBITDA mentioned in the bearish narrative aligns with the weak coverage flag, so even after the latest US$206.1 million of trailing net income, cautious investors may keep a close eye on how much cash flow actually goes toward paying debt down.

If you are concerned about how that leverage story plays out, it is worth reading how skeptics frame the downside risks in more detail 🐻 Scotts Miracle-Gro Bear Case

Valuation Signals Versus Earnings History

• At a share price of US$62.70 and a trailing P/E of 17.7x, SMG trades slightly below its peer average P/E of 18x and well below the US Chemicals industry average of 30.2x, while the DCF fair value in the data is US$84.26 and analysts are using a single allowed target of US$74.50.
• Analysts’ consensus narrative talks about product refresh, cost savings and a planned Hawthorne divestiture supporting higher margins over time. The current valuation gap between the 17.7x P/E at US$62.70, the DCF fair value of US$84.26 and the US$74.50 target creates a tension with the 19% per year earnings decline seen over the last five years.
  • On one side, trailing net income of US$206.1 million, a 5.9% net margin and a 4.21% dividend yield give some numerical backing to the idea that the business is on firmer footing than in prior loss making periods.
  • On the other, the modest 1.6% trailing revenue growth rate and history of multi year earnings contraction mean the current discount to the DCF fair value and to the US Chemicals P/E average is not clearly resolved by growth alone and needs that margin story to keep holding up.

Next Steps

To see how these results tie into long-term growth, risks, and valuation, check out the full range of community narratives for Scotts Miracle-Gro on Simply Wall St. Add the company to your watchlist or portfolio so you'll be alerted when the story evolves.

The mix of optimism and concern in this update is clear, so it makes sense to check the numbers yourself and decide where you stand. To see how the balance of positives and negatives stacks up, start with these 3 key rewards and 3 important warning signs.

See What Else Is Out There

Scotts Miracle-Gro still faces pressure from weak debt coverage, multi year earnings contraction and modest revenue growth, even as recent margins look healthier.

If those debt and earnings concerns feel uncomfortable, you can quickly compare companies with stronger financial footing by scanning the solid balance sheet and fundamentals stocks screener (45 results) today and see how they measure up.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.